BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, de Lalla F. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol. 1998;28:514-517. [PMID: 9551692 DOI: 10.1016/s0168-8278(98)80328-0] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Chen K, Wang M, Lv Z, Gu W, Wang X, Ni Q, Mu Y. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review. Horm Metab Res 2022;54:145-52. [PMID: 35276739 DOI: 10.1055/a-1749-5716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chee YJ, Tan SK, Yeoh E. Dissecting the interaction between COVID-19 and diabetes mellitus. J Diabetes Investig 2020;11:1104-14. [PMID: 32558211 DOI: 10.1111/jdi.13326] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
3 Badal D, Dayal D, Singh G, Sachdeva N. Role of DNA-LL37 complexes in the activation of plasmacytoid dendritic cells and monocytes in subjects with type 1 diabetes.Sci Rep. 2020;10:8896. [PMID: 32483133 DOI: 10.1038/s41598-020-65851-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dos Santos RS, Marroqui L, Velayos T, Olazagoitia-Garmendia A, Jauregi-Miguel A, Castellanos-Rubio A, Eizirik DL, Castaño L, Santin I. DEXI, a candidate gene for type 1 diabetes, modulates rat and human pancreatic beta cell inflammation via regulation of the type I IFN/STAT signalling pathway. Diabetologia 2019;62:459-72. [PMID: 30478640 DOI: 10.1007/s00125-018-4782-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
5 Laustsen A, Bak RO, Krapp C, Kjær L, Egedahl JH, Petersen CC, Pillai S, Tang HQ, Uldbjerg N, Porteus M, Roan NR, Nyegaard M, Denton PW, Jakobsen MR. Interferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and function. Nat Commun 2018;9:3525. [PMID: 30166549 DOI: 10.1038/s41467-018-05816-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
6 Wahid B, Wasim M, Saleem K, Waqar M, Wahid K, Hussain M, Idrees M. Poor glycemic control and abrupt onset of diabetes in HCV patients receiving direct-acting antiviral drugs: case series. Future Virology 2018;13:525-8. [DOI: 10.2217/fvl-2017-0147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Newby BN, Mathews CE. Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Front Endocrinol (Lausanne) 2017;8:232. [PMID: 28959234 DOI: 10.3389/fendo.2017.00232] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
8 Sun D, Qi W, Wang S, Wang X, Zhang Y, Wang J. Genetic Polymorphism of CYP27B1-1260 as Associated With Impaired Fasting Glucose in Patients With Chronic Hepatitis C Undergoing Antiviral Therapy. Hepat Mon 2016;16:e35179. [PMID: 27822255 DOI: 10.5812/hepatmon.35179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(5): 586-600 [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
10 Xia CQ, Peng R, Chernatynskaya AV, Yuan L, Carter C, Valentine J, Sobel E, Atkinson MA, Clare-Salzler MJ. Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production. J Immunol 2014;193:1024-34. [PMID: 24973447 DOI: 10.4049/jimmunol.1303230] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
11 Ferreira RC, Guo H, Coulson RM, Smyth DJ, Pekalski ML, Burren OS, Cutler AJ, Doecke JD, Flint S, McKinney EF. A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes. 2014;63:2538-2550. [PMID: 24561305 DOI: 10.2337/db13-1777] [Cited by in Crossref: 167] [Cited by in F6Publishing: 167] [Article Influence: 20.9] [Reference Citation Analysis]
12 Stinton LM, Myers RP, Coffin CS, Fritzler MJ. Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. BMC Gastroenterol 2013;13:50. [PMID: 23506439 DOI: 10.1186/1471-230X-13-50] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
13 Himoto T, Nishioka M. Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. Auto Immun Highlights. 2013;4:39-53. [PMID: 26000142 DOI: 10.1007/s13317-013-0046-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
14 Diana J, Simoni Y, Furio L, Beaudoin L, Agerberth B, Barrat F, Lehuen A. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med. 2013;19:65-73. [PMID: 23242473 DOI: 10.1038/nm.3042] [Cited by in Crossref: 278] [Cited by in F6Publishing: 288] [Article Influence: 27.8] [Reference Citation Analysis]
15 Wu HL, Duan ZP, Zheng SJ. Hepatitis C virus infection and autoimmunity. Shijie Huaren Xiaohua Zazhi 2012; 20(28): 2678-2684 [DOI: 10.11569/wcjd.v20.i28.2678] [Reference Citation Analysis]
16 Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012;2012:871401. [PMID: 22988469 DOI: 10.1155/2012/871401] [Reference Citation Analysis]
17 Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012;2012:871401. [PMID: 22988469 DOI: 10.1155/2012/871401] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
18 Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol. 2012;2012:871401. [PMID: 22988469 DOI: 10.1155/2012/871401].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Oka R, Hiroi N, Shigemitsu R, Sue M, Oshima Y, Yoshida-Hiroi M. Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review. Clin Med Insights Endocrinol Diabetes. 2011;4:39-45. [PMID: 22879793 DOI: 10.4137/cmed.s7815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
20 Sung H, Chang M, Saab S. Management of Hepatitis C Antiviral Therapy Adverse Effects. Curr Hepat Rep. 2011;10:33-40. [PMID: 21423320 DOI: 10.1007/s11901-010-0078-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
21 Böckle BC, Sepp NT. Hepatitis C virus and autoimmunity. Auto Immun Highlights 2010;1:23-35. [PMID: 26000104 DOI: 10.1007/s13317-010-0005-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
22 Gonzalez G, Castro FP, Berho M, Petras R. Autoimmune enteropathy associated with cessation of interferon-alpha therapy in chronic hepatitis C. Dig Dis Sci 2010;55:1490-3. [PMID: 19639409 DOI: 10.1007/s10620-009-0877-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
23 Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-44. [PMID: 19127513 DOI: 10.1002/hep.22703] [Cited by in Crossref: 203] [Cited by in F6Publishing: 181] [Article Influence: 15.6] [Reference Citation Analysis]
24 Soetekouw PM, Koopman M, Burger D, Tjan-Heijnen VC, De Mulder PH. Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma. Acta Oncol 2009;48:154-6. [PMID: 19101828 DOI: 10.1080/02841860802047403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
25 Stava CJ, Jimenez C, Vassilopoulou-Sellin R. Endocrine sequelae of cancer and cancer treatments. J Cancer Surviv 2007;1:261-74. [PMID: 18648961 DOI: 10.1007/s11764-007-0038-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
26 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
27 Chehadeh W, Lobert PE, Sauter P, Goffard A, Lucas B, Weill J, Vantyghem MC, Alm G, Pigny P, Hober D. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon. J Virol 2005;79:13882-91. [PMID: 16254324 DOI: 10.1128/JVI.79.22.13882-13891.2005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
28 Chan WB, Chow CC, Cockram CS. Interferon alpha treatment and endocrine disease. J R Soc Med 2003;96:481-5. [PMID: 14519723 DOI: 10.1258/jrsm.96.10.481] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
29 Chen LK, Hwang SJ, Tsai ST, Luo JC, Lee SD, Chang FY. Glucose intolerance in Chinese patients with chronic hepatitis C. World J Gastroenterol 2003; 9(3): 505-508 [PMID: 12632506 DOI: 10.3748/wjg.v9.i3.505] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
30 Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race. a case-control study. Am J Gastroenterol 2003;98:438-41. [PMID: 12591065 DOI: 10.1111/j.1572-0241.2003.07256.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 0.7] [Reference Citation Analysis]
31 Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci. 2002;47:1649-1654. [PMID: 12141831 DOI: 10.1023/A:1015852110353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
32 Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Mühlen A, Manns MP, Brabant G. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83. [PMID: 11171829 DOI: 10.1136/gut.48.3.378] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
33 Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, Greig PD, Lilly LB, Heathcote JE, Levy GA, Cattral MS. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000;32:87-90. [PMID: 10869293 DOI: 10.1053/jhep.2000.8270] [Cited by in Crossref: 113] [Cited by in F6Publishing: 96] [Article Influence: 5.1] [Reference Citation Analysis]